HIGH

Zydus Lifesciences Entecavir 1 mg Tablets Recalled for Impurity Degradation Issues (2025)

Zydus Pharmaceuticals USA Inc. recalls Entecavir tablets after FDA enforcement reports impurity/degradation failures. The recall affects 4,440 bottles distributed nationwide. Providers and patients should stop use and seek guidance from a healthcare professional.

Quick Facts at a Glance

Recall Date
September 4, 2025
Hazard Level
HIGH
Brands
Zydus Pharmaceuticals USA Inc., Entecavir, Zydus Lifesciences Ltd.
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
1 states
At-Risk Groups
GENERAL, PREGNANT, PETS

Hazard Information

Failed Impurity/Degradation Specifications

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Zydus Pharmaceuticals (USA) Inc or your healthcare provider for guidance. Notification method: N/A

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Entecavir tablets are an antiviral used to treat hepatitis B. They are prescription-only and require medical supervision.

Why This Is Dangerous

Impurity or degradation can affect drug purity and potency, potentially compromising treatment efficacy.

Industry Context

This recall is not part of a broader industry pattern at this time.

Real-World Impact

Consumers and healthcare providers should stop use and consult a clinician for alternatives; no injuries reported in the data.

Practical Guidance

How to identify if yours is affected

  1. Locate bottle with NDC 68382-921-06
  2. Check Lot E309377 and Exp 11/30/2025
  3. Verify 30-tablet packaging and Rx Only designation

Where to find product info

NDC on bottle, packaging insert, and the FDA recall page linked in notices

What timeline to expect

Refunds/replacements typically processed within several weeks after confirmation

If the manufacturer is unresponsive

  • Document all communications
  • Escalate to FDA consumer complaint if necessary
  • Consult healthcare provider for interim treatment options

How to prevent similar issues

  • Verify NDC before dispensing medications
  • Maintain inventory controls to isolate recalled lots
  • Monitor FDA recall updates for new information

Documentation advice

Keep bottle packaging, recall notice, and correspondence with supplier for records

Product Details

Product: Entecavir Tablets, USP 1 mg, 30 Tablets. Manufacturer: Zydus Lifesciences Ltd., Ahmedabad, India. Distributor: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534. NDC: 68382-921-06. Lot: E309377. Expiration: 11/30/2025. Quantity: 4,440 bottles. Sold nationwide in the U.S.

Reported Incidents

No specific incidents or injuries are reported in the provided data.

Key Facts

  • 4,440 bottles recalled
  • NDC 68382-921-06
  • Lot E309377
  • Exp 11/30/2025
  • Distributed nationwide in the U.S.
  • High hazard level

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANTPETS
Injury Types
POISONINGOTHER

Product Details

Model Numbers
Lot E309377
Exp 11/30/2025
UPC Codes
68382-920
68382-921
68382-920-06
+9 more
Affected States
ALL
Report Date
September 24, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more